Equest Pramox

There is no image.

Method of action: Endectocides

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Equest Pramox

Quick Facts

Property	Description
Active Ingredients	Moxidectin, Praziquantel
Form	Oral gel (palatable formulation)
Pharmacological Class	Anthelmintic, Endectocide
Common Use	Comprehensive internal parasite control in equines
Origin	Semi-synthetic (Moxidectin) and Synthetic (Praziquantel)

What is the Pharmacological Class of Equest Pramox?

Equest Pramox is defined as a veterinary endectocide and a broad-spectrum anthelmintic, classified as a prescription-only veterinary medicinal product for equines. It is characterized as a combination drug that relies on the synergy between two distinct active ingredients: Moxidectin and Praziquantel. Moxidectin is a semi-synthetic derivative of the potent macrocyclic lactone class, while Praziquantel is a synthetic compound. Moxidectin, as an antinematodal agent, offers superior duration of efficacy compared to older macrocyclic lactones due to its established lipophilic nature and sustained presence in the body. This property is clinically recognized as supporting extended protection against roundworms following administration.

Equest Pramox Composition and Dosage Form

The product's composition features the combination of Moxidectin and Praziquantel formulated into a palatable oral gel, a distinct feature designed to enhance acceptance during oral administration in horses and ponies. The medicine is supplied via a specialized calibrated syringe (e.g., SURE-DIAL syringes). This dual-compound strategy is utilized because the addition of Praziquantel is necessary for achieving high efficacy against common tapeworm species, which single-ingredient macrocyclic lactones often miss. The medicine is designed for addressing mixed parasitic infections in the target group.

General Purpose of the Moxidectin/Praziquantel Combination

The general purpose of this dual-action formulation is to achieve comprehensive parasitic control by targeting the two main parasite classes in horses within a single treatment, often used in routine rotation protocols. The distinct mechanisms—paralysis of nematodes by Moxidectin and spastic contraction of cestodes by Praziquantel—ensure that the product addresses a wide spectrum of clinically relevant mixed parasitic infections. This strategy contributes to the animal's overall health and is often employed to simplify long-term parasite management for breeding stock, foals, and active horses.

What side effects are possible with Equest Pramox?

Possible Side Effects and Safety Information

The safety profile of Equest Pramox (Moxidectin/Praziquantel) is established through official government regulatory documents. Adverse reactions reported are typically transient and are categorized by frequency and the body systems affected.

Adverse Reaction Classification

The documented side effects primarily involve the Digestive/Oral and Nervous System System-Organ Classes (SOCs).

Frequency	Examples of Documented Reactions
Rare (1-10 per 10,000 animals treated)	Hypersalivation, Mouth pain, Swollen muzzle, Ataxia (incoordination), Droopy lower lip, Anorexia.
Very Rare (less than 1 per 10,000 animals treated)	Digestive tract disorder (e.g., colic, loose stool), Tremor, Lethargy.

Serious adverse reactions are not typically categorized as such within the SOC listings; however, clinically relevant events like ataxia or colic are documented as transient and self-resolving. Mild, transient loose faeces or colic may occur in cases of very high worm burdens due to the death of parasites.

Population-Specific Safety and Restrictions

Foals: This product is contraindicated in young foals less than 6.5 months old. Transient adverse reactions may occur in foals even at the recommended dose.
Reproductive Safety: The product is considered safe for use in breeding, pregnant, and lactating mares.
Contraindications: Do not use if there is known hypersensitivity to the active substances or any excipients.
Environmental and Non-Target Species Safety: The product is toxic to aquatic organisms (fish) and dung fauna. It is harmful to dogs and cats if ingested. A withdrawal period of 64 days applies before horses may be slaughtered for human consumption.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Moxidectin/Praziquantel primarily through transient neurological signs and severe systemic effects, with risk clearly stratified by age.

Feature	Official Regulatory Statement
Documented Manifestations	The clinical presentation is characterized by transient neurological signs including ataxia (incoordination), depression, lethargy, and flaccid lower lip. These symptoms typically appear within 8 to 24 hours following administration and are documented to resolve spontaneously within 24 to 72 hours.
Severe Outcomes	Serious adverse reactions are documented, particularly in susceptible populations, which may include the onset of coma and seizures.
Population Risk	Foals are designated as more susceptible to severe adverse reactions; the product is contra-indicated for foals less than 6.5 months of age. Adult horses typically exhibit transient effects only at doses 3 times the recommended amount or greater.

Emergency Actions and Management Status

Antidote Status: The regulatory labels state that no specific antidote is known for this overdose.
Management: Symptomatic treatment is not generally necessary for the usual transient effects. Supportive treatment may be advisable in cases of severe manifestation or when treating highly susceptible individuals.
Urgent Medical Help: Immediate medical attention is required in the event of accidental human ingestion; the package leaflet must be shown to the physician immediately.

Therapeutic Uses of Equest Pramox

Equest Pramox is used for managing internal parasites that may be associated with challenging and distressing symptomatic episodes in horses. This combination treatment is relevant in clinical settings marked by heightened discomfort that may be linked to parasite burdens. The formulation is indicated for the treatment and control of various gastrointestinal parasites in horses and ponies, including small and large strongyles, tapeworms, and bots.

Control of Symptoms Related to Small Strongyle Infections

This product is applied in situations involving symptomatic discomfort from small strongyle infections. It is used when groups of symptoms appear suddenly or fluctuate, and may assist with symptomatic relief that helps patients cope more steadily with difficult episodes. The medication is considered relevant across conditions characterized by episodic or fluctuating symptom patterns related to parasite infection.

Dual-Action Management and Symptomatic Support

This treatment is relevant for easing symptoms associated with tapeworm manifestations and general parasitic burdens. It is applied in contexts where additional support for symptom management is needed and may be part of symptomatic management for parasites that can cause temporary functional strain. It is considered relevant when symptoms intensify, and it provides support that helps ease the overall symptom burden, assisting with general well-being during symptomatic phases.

Quick Fact: Symptomatic support in episodes involving parasites

Regulatory References

National Library of Medicine (NIH) DailyMed label information

Eligibility and Restrictions for Use

The eligibility profile for Equest Pramox (Moxidectin/Praziquantel) is strictly defined by official regulatory documents, focusing on species, age, and existing health status.

Eligibility Scope

Classification	Population Rule
Contraindicated	The medicine is prohibited in young foals less than 6.5 months old, establishing a strict minimum age threshold. It is also contraindicated in any animal with known hypersensitivity to Moxidectin, Praziquantel, or any excipients. Furthermore, the product must not be administered to non-equine species due to concentration risks.
Allowed Use	Licensed for Horses and Ponies aged 6.5 months and older. The medication is formally confirmed as safe for use in breeding mares, pregnant mares, and lactating mares, and administration does not negatively affect fertility.
Restrictions	Use is not authorised in mares that are producing milk for human consumption. Due to the concentration of active ingredients, special care and verified accurate dosing are explicitly required for low body weight foals to prevent an overdose risk. Use is also generally not recommended in sick or debilitated animals.

Eligibility Classifications

Official regulatory documents classify population limitations as Contraindicated (absolute prohibition), Safe for use (permitted), or Not authorised for use (prohibited based on output).

Connection to the overall eligibility profile: Regulatory authorities determine eligibility by establishing a minimum age, prohibiting use where known allergies or wrong species are involved, and by defining conditional use in animals with specific low body weight or economic purpose constraints.

What should I know about interactions with other medicines?

Officially Documented Interaction Patterns

The interaction profile for this combination medicine is defined by both pharmacodynamic potentiation involving Moxidectin and pharmacokinetic alteration involving Praziquantel, as stated in regulatory documents.

Combinations Classified as Contraindicated

Co-administration is officially contraindicated with strong Cytochrome P450 3A (CYP3A) inducers. This class includes certain medicines such as Rifampin and Phenytoin, as well as the herbal supplement St John’s Wort. These substances significantly reduce the plasma concentration of the Praziquantel component through enzyme induction, potentially leading to treatment failure.

Other Pharmacokinetic and Pharmacodynamic Interactions

Exposure-Altering Interactions (Praziquantel): CYP3A Inhibitors, such as Cimetidine, are documented to cause higher and more sustained plasma concentrations of Praziquantel, increasing exposure. Separately, consumption of Grapefruit or Grapefruit Juice may also increase Praziquantel exposure by inhibiting intestinal CYP3A4.
Pharmacodynamic Potentiation (Moxidectin): Moxidectin is documented to increase the effects of co-administered GABA agonists, which are a class of substances including certain sedatives.

Population-Specific Notes

The interaction risk related to Praziquantel is officially noted as heightened in cases of moderate to severe liver impairment. This condition alters the clearance of Praziquantel, resulting in considerably higher and longer-lasting plasma concentrations of the drug, which may affect the severity of other interactions.

Mechanism of Action

Targeting Invertebrate Neuromuscular Signaling

The moxidectin component acts as an agonist on specific ligand-gated chloride channels found in the nerve and muscle cells of susceptible nematodes. This binding causes the channels to open continuously, leading to a massive influx of chloride ions ( Cl^-). The resulting hyperpolarization of nerve and muscle membranes leads to flaccid paralysis, which culminates in the worm's expulsion from the host system.

Disruption of Tapeworm Membrane Integrity

The praziquantel component rapidly modulates the calcium ion ( Ca^2+) permeability of the tapeworm's outer layer (tegument). This action triggers an uncontrolled surge of Ca^2+ influx, initiating severe, tetanic muscle spasms and extensive vacuolization of the tegument. The structural compromise and sustained contraction allow for the parasite's destruction and clearance.

Dosage and Administration Information

How to Use Equest Pramox — Administration Guidelines

The following instructions outline the steps for administration and dosing.

Administration Details

Detail	Description
Route of Administration	Oral gel (via syringe)
Dosing Schedule	A single oral dose of 400 µg moxidectin/kg body weight and 2.5 mg praziquantel/kg body weight
Frequency	A single dose with a minimum re-treatment interval of 13 weeks for moxidectin-sensitive parasite control
Age Restriction	Do not administer to foals less than 6.5 months of age

Required Procedural Steps

Administration follows a sequence to ensure the correct dose is delivered, as the dose is dependent on the animal's weight.

Determine Body Weight: The animal's body weight must be determined as accurately as possible, with the use of a scale or weight tape recommended to check dosing accuracy.
Set the Syringe: Before administration, the syringe dial ring must be turned until the left side of the ring aligns with the animal’s body weight in kilograms, using the tick marks (one gradation per 25 kg live weight).
Administer the Gel: Place the syringe tip into the animal's mouth and administer the oral gel onto the base of the tongue.
Ensure Swallowing: The animal’s head should be raised immediately for a few seconds after application to ensure the full dose is swallowed.

Special Condition: To prevent cross-contamination, the same syringe must not be used to treat more than one animal unless they are running together or in direct contact on the same premises.

Recent Clinical Evidence

Equest Pramox: Recent Clinical Evidence

Evidence for Broad-Spectrum Parasite Management

The Moxidectin/Praziquantel combination was studied for conditions involving mixed parasitic infections, including research examining strongyles, tapeworms, and bots. Evidence was gathered through rigorous Controlled Field Studies and Regulatory Dose-Confirmation Trials. Researchers monitored outcomes related to the administration of the treatment across various populations of horses and ponies. Primary outcomes included measures such as Geometric Mean Effectiveness (an outcome measure reported against key target parasites) and Fecal Egg Count Reduction (FECR) against strongyles. The difficulty in reliably diagnosing tapeworm infection via standard field methods complicates the assessment of observed outcomes outside of controlled research environments.

Evidence for Targeting Encysted Small Strongyles

Research examined the activity of the formulation against the encysted larval stages (EL3 and L4) of small strongyles. Studies included specialized Controlled Clinical Trials exploring outcomes related to the calculated change in the number of larval stages over specific observation periods. Studies also described monitoring the Egg Reappearance Period (ERP), which tracks the time until strongyle eggs reappeared. Long-term follow-up data on sustained clearance are not fully established, and reports have described a pattern of a shortened ERP in some geographical areas.

Evidence in Key Population Groups and Research Gaps

Research monitored populations including adult horses and yearlings, and studies explored the use in mares (breeding, pregnant, and lactating). However, data for certain groups remain insufficient for an in-depth analysis of outcome variation. Research also monitored the duration of the observed outcomes through ERP assessments, typically up to 90 days. Follow-up durations were limited in many primary trials. Comparative evidence is lacking for certain long-term outcomes against all available alternative products, as research often focuses only on exploring outcomes versus a placebo or a single established product.

Key Studies & References

Quest Plus Gel - moxidectin and praziquantel gel (Veterinary - Anthelmintic) - DailyMed

Frequently Asked Questions (FAQ)

Common questions about Equest Pramox (FAQ)

Q: What is the typical time frame before the medicine starts working?

Official information describes how the two active components work on the parasites, such as the rapid disruption caused by praziquantel or the paralysis caused by moxidectin. While a specific onset of action for the full treatment effect is not provided, research has described the calculated elimination of early larval stages of small strongyles eight weeks after treatment.

Q: Does using Equest Pramox cause stomach issues?

According to official regulatory documents, digestive tract issues, such as colic or loose stool/faeces, are documented as very rare side effects. Mild, temporary loose faeces or colic are also described as potentially occurring in cases involving a very high parasite burden.

Q: Are there any known interactions with herbal products?

Official documentation specifically states that the herbal supplement St John’s Wort is contraindicated, meaning it should not be used with this medicine. This is because St John’s Wort is documented to affect certain liver enzymes that process the praziquantel component, potentially reducing the medicine’s concentration.

Q: What happens if I use Equest Pramox for a longer time than described?

Regulatory documents specify a minimum re-treatment interval of 13 weeks and administration as a single dose. The official documentation emphasizes the importance of following the stated re-treatment interval to avoid the potential for overdose symptoms.

Q: What is the risk if I accidentally take too much?

In adult animals, official documents indicate that transient adverse reactions may occur if the dose is exceeded by three times the recommended amount. The documented symptoms of overdose include lack of coordination (ataxia), depression, and a flaccid lower lip, which are generally described as resolving spontaneously.

Q: Why are there warnings about specific interactions on the label?

Warnings are present because the active ingredients in the medicine can be affected by other substances. For example, some interacting substances may significantly reduce the concentration of one drug component, potentially causing the treatment to fail, while others may increase the effects of certain co-administered substances, necessitating caution.

Q: Is Equest Pramox the same thing as Pramox?

The official name of the product is Equest Pramox. It is a combination medicine containing the two active ingredients, Moxidectin and Praziquantel, formulated together. It is distinct from other products that may share similar names or contain only one of the components.

Q: Is Equest Pramox an antibiotic?

No. Official regulatory documents classify this medicine as a veterinary endectocide and a broad-spectrum anthelmintic for the control of internal parasites, not an antibiotic.

Q: How long does Equest Pramox stay in your system?

Official documents describe the moxidectin component as having a lipophilic (fat-soluble) nature, which is associated with a sustained presence in the body. This characteristic supports its extended period of protection. The withdrawal period—the time before an animal can be slaughtered for human consumption—is officially set at 64 days.

Q: Does Equest Pramox require a prescription?

Yes. Regulatory documents classify this product as a prescription-only veterinary medicinal product for equines. This means it must be prescribed by a veterinarian.

Q: Are there any long-term effects associated with using Equest Pramox?

The reported adverse reactions described in the official safety data are generally categorized as transient and are expected to resolve naturally. The safety profile focuses on short-term adverse reactions; information about long-term effects extending significantly beyond the primary clinical studies is not detailed.

Q: What is the general duration of action for Equest Pramox?

Official regulatory documents state that the egg reappearance period (ERP) for small strongyles is officially 90 days, which is approximately 13 weeks. This period is described in official documents as the product’s extended duration of protection against the reappearance of these specific parasite eggs.

Q: Are skin rashes a reported side effect of Equest Pramox?

While the main tables of adverse reactions do not list 'skin rash,' official documents note that a known hypersensitivity (allergic reaction) to the active substances or any excipients is an official contraindication. Rare transient reactions like a swollen muzzle have also been documented.

Q: Can Equest Pramox be taken at the same time as supplements?

The interaction profile specifically lists the herbal supplement St John’s Wort as a contraindication because it affects how the medicine is processed in the body. The risk mechanism of affecting liver enzymes is known, but general information is not available for all supplements.

Q: What are the known severe or serious side effects of Equest Pramox?

The safety profile includes clinically relevant events such as ataxia (incoordination) and colic, which are categorized by frequency (rare or very rare). These events are consistently described in official documents as being transient and resolving without intervention.

Q: Are there any food or drink restrictions while using Equest Pramox?

The official interaction profile notes that consumption of Grapefruit or Grapefruit Juice may increase the exposure to the praziquantel component. This is due to grapefruit inhibiting certain enzymes that process the medicine in the body.

Q: Are there different strengths of Equest Pramox available?

Official product information describes a single standardized concentration, Equest Pramox 19.5 mg/g + 121.7 mg/g oral gel. No other strengths are officially listed in the quantitative composition section of the regulatory documents.

Q: What is the difference between Equest Pramox and similar sounding medications?

The key distinguishing factor is its official composition: the combination of two specific active ingredients, Moxidectin and Praziquantel. Regulatory documents confirm that the dual-compound strategy is required to achieve high efficacy against both roundworms and tapeworms, which separates it from single-ingredient treatments.

Q: What makes Equest Pramox different from similar over-the-counter options?

This medicine is classified as a prescription-only veterinary medicinal product for equines. This legal classification means veterinary authorization is necessary for its use, setting it apart from options available without a prescription.

Q: Why is the dosage route so important for Equest Pramox?

Official administration instructions require the oral gel to be administered precisely to the base of the tongue. This route is defined to support the successful delivery of the full, accurate dose, which is integral for the treatment to be effective as described.

How should Equest Pramox be stored and disposed of?

The storage and disposal of Equest Pramox Oral Gel must strictly adhere to regulatory requirements for product stability, child safety, and environmental protection.

Storage Condition	Requirement
Temperature	Do not store above 25 °C.
Stability	Use within 6 months after opening the syringe.
Child Safety	Keep out of the reach and sight of children.

All unused product and waste material must be disposed of in accordance with local requirements. Due to its toxicity to aquatic organisms, the product and used syringes must not contaminate ponds, waterways, or ditches. Furthermore, treated horses should not have access to watercourses during the first week after treatment to limit environmental exposure to moxidectin.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.